These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30083415)

  • 1. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential.
    Mulcahy AW; Hlavka JP; Case SR
    Rand Health Q; 2018 Mar; 7(4):3. PubMed ID: 30083415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
    Dickson SR; Kent T
    JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
    Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
    J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner.
    Campen CJ
    J Adv Pract Oncol; 2017; 8(7):688-699. PubMed ID: 30333932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Legal and Regulatory Status of Biosimilars: How Product Naming and State Substitution Laws May Impact the United States Healthcare System.
    Paradise J
    Am J Law Med; 2015; 41(1):49-84. PubMed ID: 26237983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Projected US savings from biosimilars, 2021-2025.
    Mulcahy A; Buttorff C; Finegold K; El-Kilani Z; Oliver JF; Murphy S; Jessup A
    Am J Manag Care; 2022 Jul; 28(7):329-335. PubMed ID: 35852882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019.
    García-Goñi M; Río-Álvarez I; Carcedo D; Villacampa A
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33918795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economics of biosimilars.
    Blackstone EA; Joseph PF
    Am Health Drug Benefits; 2013 Sep; 6(8):469-78. PubMed ID: 24991376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic Drugs, Biosimilars, and Barriers to Entry.
    Shepherd JM
    Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The complexities of biosimilars and the regulatory approval process.
    Lucio S
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers To US Biosimilar Market Growth: Lessons From Biosimilar Patent Litigation.
    Van de Wiele VL; Kesselheim AS; Sarpatwari A
    Health Aff (Millwood); 2021 Aug; 40(8):1198-1205. PubMed ID: 34339242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars in the United States: Emerging Issues in Litigation.
    Wong AY; Rumore MM; Chan AW
    BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.